At the Cell and Gene Meeting on the Mesa, a panel discussion was held on advanced therapy production and how it demands ...
The awarded $1.7 million in funding will support the company’s preclinical and clinical progress on DMX-1001 (noribogaine), ...
The growing demand for liquid medicines is increasingly driven by the unique needs of several distinct patient groups, improving compliance in these demographics through flexible, palatable dosing ...
The licensing of Talicia, an FDA-approved fixed-dose therapy, to key at-risk markets strategically combats an increasingly ...
Siegfried Schmitt, PhD, vice-president, Technical at Parexel, answers questions on the use and benefits of real-world ...
Pharmaceutical Technology® spoke with Juliana Maynard, PhD, Head of Translational Imaging, at Medicines Discovery Catapult, ...
In this continuation of a three-part series, the author explores the potential use of agentic AI in pharmaceutical R&D.
The 100% tariff on imported drugs will pressure pharma companies to build manufacturing sites in the US or face significant ...
Pharmaceutical Technology® spoke with Bryan Miller, Director of Scientific and Technical Operations at Crown Bioscience UK, ...
Pfizer re-balances weight loss portfolio with Metsera, Bristol Myers Squibb and Roche make Breast cancer progress, and ...
Alvin Jogasuria, ProBio; Matthew Lunning, University of Nebraska Medical Center; and Carl Schoellhammer, DeciBio, go behind ...
AI and ML enhance drug discovery by rapidly screening compounds and predicting ADMET properties, reducing resource commitment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback